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ABSTRACT
Background. Sentinel lymph node (SLN) surgery is used
worldwide for staging breast cancer patients and helps limit
axillary lymph node dissection. [99mTc]Tilmanocept is a
novel receptor-targeted radiopharmaceutical evaluated in 2
open-label, nonrandomized, within-patient, phase 3 trials
designed to assess the lymphatic mapping performance.
Methods. A total of 13 centers contributed 148 patients
with breast cancer. Each patient received [99mTc]tilmano-
cept and vital blue dye (VBD). Lymph nodes identified
intraoperatively as radioactive and/or blue stained were
excised and histologically examined. The primary end-
point, concordance (lower boundary set point at 90 %), was
the proportion of nodes detected by VBD and
[99mTc]tilmanocept.
Results. A total of 13 centers contributed 148 patients who
were injected with both agents. Intraoperatively, 207 of
209 nodes detected by VBD were also detected by
[99mTc]tilmanocept for a concordance rate of 99.04 %
(p \ 0.0001). [99mTc]tilmanocept detected a total of 320
nodes, of which 207 (64.7 %) were detected by VBD.
[99mTc]Tilmanocept detected at least 1 SLN in more
patients (146) than did VBD (131, p \ 0.0001). In 129 of
131 patients with C1 blue node, all blue nodes were
radioactive. Of 33 pathology-positive nodes (18.2 %
patient pathology rate), [99mTc]tilmanocept detected 31 of
33, whereas VBD detected only 25 of 33 (p = 0.0312). No
pathology-positive SLNs were detected exclusively by
VBD. No serious adverse events were attributed to
[99mTc]tilmanocept.
Conclusion. [99mTc]Tilmanocept demonstrated success in
detecting a SLN while meeting the primary endpoint.
Interestingly, [99mTc]tilmanocept was additionally noted to
identify more SLNs in more patients. This localization
represented a higher number of metastatic breast cancer
lymph nodes than that of VBD.
Sentinel lymph node (SLN) identification during breast
surgery has been extensively validated.1–6 In current SLN
biopsy practice, a vital blue dye (VBD) may be paired with
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a colloidal radiotracer with the intent to complement its
performance by increasing SLN detection rate and identi-
fication accuracy.7,8 However, the overall efficacy of SLN
identification depends heavily on the specificity of the
agent(s) used in the mapping procedure in order to provide
reliable localization and retention of the agent in the sen-
tinel node(s).
[99mTc]Tilmanocept (Fig. 1) is a novel, engineered radio-
pharmaceutical specifically designed for lymphoscintigraphy
and intraoperative SLN detection.9 [99mTc]Tilmanocept
consists of multiple DTPA and mannose moieties tethered to a
dextran scaffold. DTPA chelates and holds 99mTc, while its
multiple mannose moieties facilitate specific multivalent
binding to mannose receptors (CD206) expressed on the
surfaces of reticuloendothelial cells residing within lymph
nodes.10 Preclinical studies and several phase 1 and phase 2
clinical trials demonstrated that [99mTc]tilmanocept’s chem-
ical structure and relatively small molecular size (MW =
16.7 kDa) and small molecular diameter of 7.1 nm enable
[99mTc]tilmanocept to exit its injection site more rapidly than
radiolabeled colloids and quickly accumulate at the SLNs,
while specific multivalent interactions between its mannose
moieties and CD206 enable avid binding to target receptors
and retention in SLNs for up to 30 h, without observed transit
to second-echelon lymph nodes.9–15
The clinical trials reported here were designed in consul-
tation with the US Food and Drug Administration and the
European Medicine Agency for the application of [99mTc]til-
manocept for approval as a new drug. Here, we report the
results from 2 highly similar prospective, phase 3 clinical trials
of [99mTc]tilmanocept in patients undergoing SLN mapping
for breast cancer. The results from the melanoma patients are
reported separately in a companion paper.16 On March 13,
2013 the US Food and Drug Administration approved
[99mTc]tilmanocept for intraoperative lymph node mapping.
MATERIALS AND METHODS
Study Design
From June 2008 to April 2011, 2 highly similar phase 3
trials were performed on breast cancer patients without
presurgical evidence of lymph node metastases who were
scheduled for surgeries that included clinically indicated
SLN mapping. The primary aim of both studies was to
evaluate the concordance of [99mTc]tilmanocept with VBD,
a mapping agent that is routinely used to identify SLNs. The
studies were designed as prospective, phase 3, open-label,
nonrandomized, within-patient trials in which all patients
received both [99mTc]tilmanocept and a VBD (Lymphazu-
rin). The first trial involved 8 centers enrolling at least 1
breast cancer patient between June 2008 and June 2009. A
second trial was conducted to extend the safety database to
500 subjects (including phase 1 and 2 trials). The second
trial involved 5 sites enrolling breast cancer patients from
July 2010 to April 2011 and used the same study design and
procedures. These studies were powered at 0.8 or greater for
the primary endpoint. All patients gave written informed
consent. The Western Institutional Review Board and
institutional review boards at each enrolling institution
approved the protocol, patient instructions, and informed
consent documentation. Both studies complied with all
provisions of the Declaration of Helsinki and US laws
requiring registration and updates via ClinicalTrials.gov
(trial No. NCT00671918 and NCT01106040). This report
describes results obtained from the breast cancer patients
who participated in these studies.
Enrollment criteria included the histologically con-
firmed presence of unilateral breast cancer with a surgical
treatment plan that included SLN mapping. The complete
list of criteria is presented in Table 1. The studies defined 3
FIG. 1 [99mTc]Tilmanocept is composed of a dextran backbone
(black) to which are attached multiple units of mannose (green) and
DTPA (blue). The mannose units provide a molecular mechanism by
which [99mTc]tilmanocept avidly binds to a receptor specific to
recticuloendothelial cells (CD206), and the DTPA units provide a
highly stable means to radiolabel tilmanocept with technetium-99m
(red). The molecular weight of [99mTc]tilmanocept is approximately
17,000 grams per mole; the molecular diameter is 7.1 nm
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populations of patients: a population of all enrolled
patients, an intent-to-treat (ITT) population, and the safety
population. The ITT population consisted of all enrolled
patients receiving both [99mTc]tilmanocept and VBD and
who had at least one histologically confirmed lymph node
stained by VBD. This was the population in which the
concordance of [99mTc]tilmanocept to VBD could be
assessed, hence the ITT designation. Analyses of pathology
rates were based on findings from any patient injected with
[99mTc]tilmanocept and from whom lymph nodes were
removed. Drug safety was based on the safety population,
consisting of all patients who received [99mTc]tilmanocept
whether or not they received VBD.
Site qualification required that all participating surgeons
and investigators had performed at least 30 SLN proce-
dures with a radiopharmaceutical within the past 90 days
prior to initiation of the trial.
Procedures
Patients received 3.0 nmol of [99mTc]tilmanocept
(50 lg). Patients scheduled for surgery on the same day as
the injection received *0.5 mCi of [99mTc]tilmanocept.
Patients scheduled for ‘‘next-day’’ surgery received
*1.0–2.0 mCi of [99mTc]tilmanocept. The radiopharma-
ceutical was administered using one of the following routes
of administration: intradermal, subareolar, or peritumoral.
For a given patient, isosulfan blue was injected after
[99mTc]tilmanocept at the time of surgery using the same
injection route as the radiopharmaceutical. Injections of
[99mTc]tilmanocept were not accompanied by either topical
application of or coinjection with local anesthetics.
Intraoperative identification of SLNs was based on three
criteria. The first criterion was visual identification of VBD
in a node and/or the afferent lymphatic channel; all blue-
stained nodes were removed and designated as ‘‘blue.’’
Observation of radioactivity in a lymph node, indicating the
localization of [99mTc]tilmanocept, formed the basis of the
second criterion. Background radioactivity levels were
measured using a handheld intraoperative gamma detector/
probe (programmed to read out in counts per second) at the
skin surface well away (not less than 20 cm) from the
injection site. The background count rate was recorded
directly from the display of the gamma detection system. The
standard deviation of the background was calculated as the
square root of the total number of counts acquired during the
measurement, which equaled the background count rate, in
counts per second, times the duration of the counting time, in
seconds. To qualify as a hot node, the intraoperative counts in
the node had to exceed the background count (using either
one 10-second count or the average of three 2-second counts,
with background measured directly on the patient C20 cm
from the primary site) plus 3 times the standard deviation of
the background and exceed 25 counts per second. The
‘‘3-sigma rule,’’ was selected for this study based on statistical
rigor; using this rule provides 99.7 % certainty that detection
of the ‘‘hot’’ node did not occur due to chance. Blue nodes
were evaluated for radioactivity prior to and after excision.
The third SLN identification criterion was based on
appearance and feel; visibly or palpably abnormal lymph
nodes were designated as palpable masses and were excised
regardless of agent localized. Mapping was considered
complete when all nodes meeting any of the 3 criteria had
been removed and all remaining nodes in the basin were
designated as negative based on these criteria. All excised
nodes and tissues underwent histopathological evaluation
that included hematoxylin and eosin staining and immuno-
histochemical analysis. Based on tissue analysis, tissue
organization was confirmed (lymph node) and pathology
status was determined.
Safety Data
The safety endpoint was monitored by performing fol-
low-up safety labs, EKGs, and physical examinations
6–30 h postinjection and comparing results with baseline
values. All patients were monitored for adverse events.
Adverse events were considered severe if they resulted in
death, represented a life-threatening reaction, or required
TABLE 1 Study enrollment criteria
Inclusion criteria
Confirmed presence of primary breast cancer
Candidate for surgical intervention, with lymph node mapping
being part of the surgical plan
At least 18 years of age at time of consent
ECOG performance status of grade 0–2
If female, either negative pregnancy test within 72 h prior to
[99mTc]tilmanocept administration, having been surgically
sterilized, or postmenopausal for at least 1 year prior to start of
study
Pure ductal carcinoma in situ (DCIS) or noninvasive carcinoma with
lymph node biopsy as part of the surgical plan
Exclusion criteria
Pregnancy or lactation
Clinical or radiological evidence of metastatic cancer, including
palpably abnormal or enlarged lymph nodes
Known hypersensitivity to Lymphazurin or patent blue V
Participation in another investigational drug study
Bilateral primary breast cancers or multiple breast tumors
Prior surgical breast surgery (e.g., axillary surgery, implants)
Scheduling for bilateral mastectomy if bilateral SLN mapping is
required
Preoperative radiation therapy to the affected breast or axilla
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prolonged or readmission to the hospital. The principal
investigator for each site was responsible for determining if
adverse events were definitely not, probably not, possibly,
probably, or definitely related to [99mTc]tilmanocept
administration. The safety data was analyzed with para-
metric statistics if the test results were reported as
continuous variables.
Statistical Plan
The primary efficacy endpoint in both studies was the
concordance of radioactive lymph nodes identified with
[99mTc]tilmanocept and those identified with VBD. Con-
cordance of [99mTc]tilmanocept with VBD was defined as
the number of blue-stained nodes that were detected by
[99mTc]tilmanocept, divided by the number of blue-stained
lymph nodes. A supportive secondary endpoint was the
patient concordance rate defined as the number of patients
for whom all nodes detected by VBD were also detected by
[99mTc]tilmanocept, divided by the number of patients with
at least one blue-stained lymph node (ITT population).
Other secondary efficacy endpoints included the propor-
tions of all removed lymph nodes that were detected by
[99mTc]tilmanocept and/or VBD. The proportions of
pathology-positive lymph nodes that were blue and/or
radioactive were evaluated, including calculation of failed
detection rates for the imaging agent. Concordance (R) was
tested in a pooled analysis with the hypothesis H0:
R B 0.90 versus Ha: R [ 0.90. A 95 % confidence interval
for the concordance rate was calculated using a large
sample normal approximation.
Role of the Funding Source
Navidea Biopharmaceuticals (Dublin, OH) sponsored
these trials and supplied tilmanocept kits for radiolabeling
to each study site. STATKING Clinical Services (Fairfield,
OH), an independent data analysis group, facilitated inde-
pendent data auditing and analyses.
RESULTS
Patient Population
A total of 152 women with breast cancer were enrolled in
the 2 trials, and 149 were injected with [99mTc]tilmanocept
(3 patients withdrew prior to injection). Therefore, 149
made up the safety population (all patients receiving
[99mTc]tilmanocept). All breast cancer patients were
female. The safety population’s average age was 58.0 years
(range, 31–84 years). Specific demographics of the various
subpopulations of the safety population are listed in
Table 2. One patient injected with [99mTc]tilmanocept was
not injected with VBD. All surgeons involved in both trials
had at least 10 years of experience performing sentinel
lymph node mapping of breast cancer.
Intraoperative Node Identification
There were 148 patients injected with both [99mTc]til-
manocept and VBD and who underwent surgery, of which
131 (88.5 %) had at least one blue node (ITT population)
and 146 (98.6 %) had at least one radioactive node
(Table 3). The observation that [99mTc]tilmanocept detec-
ted SLNs in more patients than VBD (98.6 vs 88.5 %) was
statistically significant (p \ 0.0001). A single breast cancer
patient had two palpable lymph nodes missed upon pre-
enrollment review (later found to contain cancer) that were
neither blue-stained nor radioactive. Prospectively, per
protocol, these nodes were defined as SLNs.
There were 326 lymph nodes examined in these studies.
Of 131 patients with at least 1 blue node (ITT population),
an average of 1.60 blue nodes were detected per ITT
patient for a total of 209 blue nodes. Of 146 patients with at
least one radioactive node, an average of 2.16 radioactive
nodes were detected per patient for a total of 320 radio-
active nodes. Also, 15 patients with at least one radioactive
node had no blue nodes.
TABLE 2 Demographics of patients receiving [99mTc]tilmanocept
Characteristic N = 149
Male, female 0, 149
Age, median (range) (years) 58.0 (31–84)
Weight, median (range) (lb) 154.8 (70–325)
Race
White 132
Black 6
Asian 10
Native Hawaiian or other 1
Pacific Islander 0
Ethnicity
Non-Hispanic 131
Hispanic 10
Unknown 8
Tumor stage
TX 1
Tis 14
T1 104
T2 27
T3 1
T4 2
Includes 2 patients who never received vital blue dye and are
excluded from concordance analyses
N number of patients injected with tilmanocept
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Figure 2 is a fused sagittal cross section acquired by
SPECT/CT imaging at 1 h postinjection. The cross section
visualizes a sentinel lymph node (arrow) and the injection
site. At 5 h after injection, 3 blue and hot lymph nodes
(6,724 cps at arrow, 1,477 cps, 167 cps) were detected at
surgery and excised. Pathologic examination revealed 1
pathology positive lymph node (blue with 6,724 cps,
1.7 9 1.3 9 0.7 cm) and 2 pathology negative lymph
nodes.
Concordance of [99mTc]Tilmanocept and Vital Blue
Dye
The primary efficacy endpoint in both studies was the
concordance of radioactive lymph nodes identified with
[99mTc]tilmanocept and those identified with VBD. Of 209
blue lymph nodes identified in the ITT population, 207
(99.04 %, 95 % CI = 96.59–99.88 %) were also radioac-
tive (Table 4). This concordance rate was statistically
significant (p \ 0.0001), convincingly rejecting the null
hypothesis of B90 %. For 129 of 131 patients in the ITT
population, all blue nodes were also radioactive for a
pooled patient concordance rate of 98.47 %.
Pathology Findings
Of the 148 injected with both [99mTc]tilmanocept and
VBD and who underwent surgery, a subset analysis was
performed on the 27 patients in which 1 or more pathology-
positive lymph nodes were detected (Table 3). A total of 33
pathology-positive nodes were detected in these 27
patients. All metastases were identified by hematoxylin and
eosin staining and were greater than 2 mm. Except for 2
cancer-containing palpable lymph nodes found in 1 patient
in the first study (mentioned previously), all pathology-
positive lymph nodes were radioactive. Conversely, while
[99mTc]tilmanocept detected 31 of 33 cancer-containing
lymph nodes (93.9 %), VBD identified only 25 of 33 such
nodes (75.8 %), missing the involved pathology-positive
lymph node(s) in 6 patients (22.2 %). In fact, 2 patients
(2 of 148; 1.35 %) had their nodal disease status upstaged
by [99mTc]tilmanocept findings alone; no patients were
upstaged by VBD alone. Thus, [99mTc]tilmanocept exhib-
ited a higher detection rate for disease-positive lymph
nodes than VBD on a per node and per patient basis. The
nodal failed detection rate over both studies for
[99mTc]tilmanocept was 6.06 %, whereas VBD’s nodal
failed detection rate was a significantly greater at 24.24 %
(p = 0.0312).
Adverse Events
No patient deaths were reported on study. A total of 74
adverse events occurred in 49 patients in the safety popula-
tion of breast cancer patients receiving [99mTc]tilmanocept
(N = 149). The most common events included nausea, ser-
oma, and urinary tract infection. There were 3 serious
adverse events reported from 3 patients (modified radical
mastectomy, herpes zoster ophthalimic, and cellulitis), none
of which was deemed ‘‘probably’’ or ‘‘definitely’’ related to
TABLE 3 Intraoperative mapping results
Measurement Pooled
analysis
Patients injected with both vital blue dye and
[99mTc]tilmanocept
N = 148
Detection rate,a No. of patients (%)
Blue (ITT patients) 131 (88.5)
Radioactive 146 (98.6)
p value, blue vs. radioactiveb \0001
Detection rate, No. of nodes (%) 326
Blue 209 (64.1)
Radioactive 320 (98.2)
p value, blue vs radioactiveb \0001
Average blue nodes per ITT patient, No. 1.60
ITT patients with C1 radioactive node, No. (%) 131 (100.0)
Average radioactive nodes per patient, No. 2.19
Patients with C1 blue node, No. (%) 131 (89.7)
Pathologically positive lymph nodes 33
Blue and radioactive, No. (%) 25 (75.8)
Blue and not radioactive, No. (%) 0 (0.0)
Radioactive and not blue, No. (%) 6 (18.2)
Not blue and not radioactive, No. (%)c 2 (6.1)
Pathologically positive node detection rate
Vital blue dye, No. (%) 25 (75.8)
[99mTc]tilmanocept, No. (%) 31 (93.9)
p valueb 0.0312
Failed detection rate by node
Vital blue dye (%) 24.24
[99mTc]tilmanocept (%) 6.06
p valueb 0.0312
Patients with missed positive nodesd
No. of patients with at least 1 pathologically positive
node
27
C1 node missed by vital blue dye, No. (%) 6 (22.2)
C1 node missed by [99mTc]tilmanocept, No. (%)c 1 (3.7)
N number of patients injected with both [99mTc]tilmanocept and vital
blue dye and who underwent surgery, blue blue-stained lymph node,
radioactive radioactive lymph node (see Methods section)
a At least 1 lymph node
b 2-sided p value for exact McNemar’s test
c Both nodes from the same patient, both nodes were palpably
enlarged and tumor replaced
d From patients injected with both [99mTc]tilmanocept and vital blue
dye and who underwent surgery
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[99mTc]tilmanocept. The remaining adverse events were
generally considered mild. There were no immediate or
delayed hypersensitivity reactions to [99mTc]tilmanocept.
None of the events that were considered clinically significant
was related to the administration of [99mTc]tilmanocept.
Even though local analgesics were not used in conjunction
with administration of the [99mTc]tilmanocept, only 2
patients reported injection site pain or slight breast pain
during injection related to study drug. Both of these adverse
events were considered mild and resolved the same day as
onset.
DISCUSSION
In this pooled analysis of breast cancer patients partici-
pating in 2 highly similar phase 3 trials, [99mTc]tilman-
ocept’s identification of lymph nodes was highly concordant
with identification by VBD. Of the 209 lymph nodes iden-
tified by VBD, 207 were also identified by [99mTc]tilman-
ocept (p \ 0.0001). Interestingly, VBD failed to identify a
SLN in 17 of 148 breast cancer patients (11.5 %). This was
less than the reported failure rate for VBD.17 Within these 17
patients, [99mTc]tilmanocept identified at least 1 node in all
but 2; notably, these patients also had no blue nodes. There
were significantly (p \ 0.0001) more radioactive nodes
(SLN = 320) than blue nodes (SLN = 209). Of 320 radio-
active nodes, only 207 (64.69 %) were also blue. Similarly,
in only 78 of 146 patients (53.42 %) with at least 1 radio-
active node were all the radioactive nodes also blue. Our
findings are consistent with those of Krag and coworkers,
where the isotope was better than VBD in all aspects.18
[99mTc]Tilmanocept’s ability to identify more cancer-
containing nodes than VBD (31 vs. 25, p \ 0.0312) dem-
onstrates that [99mTc]tilmanocept provides a benefit in
intraoperative lymphatic mapping beyond that provided by
VBD alone. Recent reports that local recurrence and survival
are not affected by full node dissection after positive sentinel
node biopsy in breast conservation patients accentuates the
importance of the performance of the [99mTc]tilmanocept
SLN mapping agent in these studies and points to the need to
accurately assess lymph nodes in order to optimize post-
surgery management of the patients.1, 19, 20 Our findings
TABLE 4 [99mTc]Tilmanocept concordance with vital blue dye
Concordance rate
Patienta Lymph nodeb
Total N Concordant N (%) Total SLN Concordant SLN (%)
Pooled analysis 131c 129 (98.47) 209 207 (99.04)
95 % CId (94.59–99.81) (96.59–99.88)
p valuee 0.0002 \0.0001
N number of ITT patients, SLN number of lymph nodes
a Patient concordance rate: the number of patients for whom all nodes detected by vital blue dye were also detected by [99mTc]tilmanocept
divided by the number of patients with at least 1 blue-stained lymph node
b Lymph node concordance rate: the number of blue-stained nodes that were detected by [99mTc]tilmanocept divided by the number of blue-
stained lymph nodes
c The intent-to-treat population
d 95 % exact binomial confidence interval for pooled analysis proportion
e 2-sided p value for exact 1-sample binomial test of pooled analysis concordance against null hypothesis of B90 %
FIG. 2 Lymphoscintigraphy of a 35-year-old woman with carcinoma
in situ of the left breast showing 2 intense foci of noted [99mTc]til-
manocept localization within the left axilla. An intradermal injection
(0.4 mL, 0.5 mCi, 3.0 nmol) of [99mTc]tilmanocept was administered
to the upper left quadrant of the left breast. The SPECT/CT image is a
fused sagittal cross section acquired 1 h postinjection, which visual-
izes a sentinel lymph node (arrow) and the injection site. At 5 h after
injection, 3 blue and hot lymph nodes (6,724 cps, 1,477 cps, 167 cps)
were detected at surgery and excised. Pathologic examination
revealed 1 histologically positive lymph node (blue with 6,700 cps,
1.7 9 1.3 9 0.7 cm) and 2 negative lymph nodes
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suggest, then, there is significant clinical utility in knowing
which patients have multiple positive sentinel nodes.
Entrance of a patient into the clinical trial was at the
discretion of the surgeon. As long as the patient did not
have metastatic disease, clinically positive lymph nodes, or
any of the exclusion criteria listed in Table 1, the patient
was eligible for the study. If the 2 T4 patients were
excluded the concordance would be slightly higher and the
performance of VBD would appear to be better. This is
because in one of the patients VBD failed to stain a dis-
ease-positive lymph node. Two patients were stage T4.
Both patients had 2 ‘‘hot’’ lymph nodes. Both nodes of one
patient were disease-positive with 1 of the lymph nodes not
stained blue. The other patient had a ‘‘hot’’ and ‘‘blue-
stained’’ lymph node that was disease-positive; the second
‘‘hot’’ lymph node was disease-negative and not stained
blue. Based on criteria other than T staging, for example,
N0, M0, there is no reason to exclude such patients.
There is a growing discussion as to whether or not a
complete node dissection is necessary.3,19,21 [99mTc]Tilma-
nocept identified numbers of patients who had additional
pathology-positive sentinel nodes, while VBD did not. A
study site, University of California, San Diego, had 20 breast
cancer patients with pathology-positive nodes identified
with at least 1 radioactive and/or blue sentinel node; 16 had
only a single radioactive and blue positive sentinel node.
Also, four patients had additional radioactive pathology-
positive nodes that were not blue, deeming them ‘‘multinode
positive patients.’’ The indication that [99mTc]tilmanocept
may be able to better identify multinode pathology-positive
patients may be important to the future of breast cancer
treatment. Specifically, extended field radiation therapy will
be offered to these patients if not full node dissection. To the
extent that [99mTc]tilmanocept accumulates at that the target
tissue based on a specific biochemical interaction (CD206
receptor-targeted), this molecule represents the current
generation of imaging technology and is specifically
designed to match the biochemical requirements of the
clinical problem. Thus, the increase in found disease repre-
sents a notable finding related to the SLN procedure,
especially where this is translated to a large patient popula-
tion. If blue dye alone were used, the addition of tilmanocept
could potentially change the diagnosed number of positive
nodes in 1.35 % of our nation’s 190,000 or so breast cancer
patients, which is roughly 2,000 patients per year. Since
adjuvant decisions are now often based on sentinel node
biopsy results alone, accurately knowing those patients who
have multiple positive nodes may change radiation and
systemic therapy choices.
Vital blue dye was chosen as the comparator in these
studies because it is routinely used in current practice to
identify SLNs during breast cancer surgery and has a his-
tory as a validation agent for SLN biopsy.6,22 Radioactive
colloids have been used off-label with the intent to aug-
ment VBD.7,8,23 However, [99mTc] sulfur colloid injection
(SCI) has recently been granted FDA approval in the
United States for lymphatic mapping during breast cancer
operations only. Nevertheless, radiocolloids remain an
unstandardized SLN mapping agent, mitigating their utility
as a valid comparator agent. VBD usage permitted a rig-
orous, within-patient experimental design, significantly
increasing the statistical power. There is a possibility
despite finding one blue node and finding several hot
nodes, that a rare additional aberrant blue node was missed
somewhere. It is also possible when no blue node was
identified at all and several hot nodes were found, that
again a distant blue node may have been overlooked.
However, most of the positive axilla did go on to full node
dissection, and no further blue nodes were identified.
These phase 3 studies provided a basis with which to
compare the performance of the radiolabeled colloids via
meta-analysis. A recent review of SCI was based on a
meta-analysis of 15 studies involving 9,213 breast cancer
patients receiving both SCI and VBD.24 In the meta-anal-
ysis, SCI and VBD detected at least 1 lymph node in 94.1
and 85.1 % of patients, respectively. In the current studies,
[99mTc]tilmanocept and VBD detected at least 1 lymph
node in 98.6 % (146 of 148) and 88.5 % (131 of 148) of
patients, respectively. Lastly, we constructed a meta-
analysis of these phase 3 trials and contrasted the results
against the recently published selected performance data of
Nanocoll.25 Tilmanocept had superior SLN localization
rate (99.9 vs. 95.1 %) and a higher degree of localization
(2.16 vs. 1.66 SLN per study) (p \ 0.0001). Such com-
parisons will be duplicated with larger sample sizes if
[99mTc]tilmanocept becomes commercially available.
These phase 3 trial and the previous phase 1 and 3
studies provided preliminary data regarding the perfor-
mance of [99mTc]tilmanocept compared with the current
SLN agents. First, [99mTc]tilmanocept is a wholly stan-
dardized synthetic molecule with a defined molecular
structure that permits rapid uptake into lymph nodes. When
imaged within 10 min postinjection, at least 1 ‘‘hot’’ lymph
node was detected in 98 % of the early images. Second,
based on physician use reports, the administration of
[99mTc]tilmanocept is associated with significantly less
pain and discomfort than for radiolabeled colloids. Third,
based on the contrasts of dosimetry and preoperative
imaging, [99mTc]tilmanocept exits its injection site signif-
icantly quicker than radiolabeled colloids, creating less
shine-through, thus facilitating better step-down for
observation of SLNs that reside near injection sites.15
Finally, both in vivo imaging and in vitro analysis of
[99mTc]tilmanocept’s receptor binding properties indicate it
binds specifically to SLNs and does not move downstream
to distal lymph nodes, permitting high confidence that a
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‘‘hot’’ lymph node found during a ‘‘next-day’’ surgery is a
sentinel lymph node.9,15,26 This factor also allows the
patient to be imaged as early as 10 min and as late as 24 h
or more after injection. These attributes will translate into
greater scheduling flexibility in nuclear medicine and
operating room without sacrificing either short-term or
long-term SLN detection success.
[99mTc]Tilmanocept is a modern radiopharmaceutical
designed on a chemical platform that permits future devel-
opment.26 Technetium-99m-labeled antimony sulfide
colloid and sulfur colloid, both of which were developed
more than 35 years ago, cannot be chemically modified.27,28
The chemical design of tilmanocept permits the facile
attachment of additional imaging reporters, such as fluores-
cent dyes.29,30 Routine optical imaging via robotic-
assistance or intraoperative hand-held imaging will require
the covalent attachment of the fluorescent tag to the molec-
ular imaging agent.31,32 Optical imaging would facilitate
intraoperative administration, which may be more compat-
ible with SLN mapping of lung, GI, and GU cancers. The
DTPA chelators of tilmanocept (Fig. 1) permit radiolabeling
with different radioisotopes, such as gallium-68 or indium-
111 or paramagnetic atoms.33 Gallium-68, which is a gen-
erator-produced positron-emitter, enables PET/CT hybrid
imaging.34 PET imaging provides higher sensitivity and
spatial resolution, as well as greater scatter and attenuation
correction than SPECT. Hybrid imaging with PET/CT may
prove to be more compatible for preoperative pelvic imaging
of prostate cancer. Lastly, Nanocoll is a microcolloid of
human serum albumin and must be tested for antibodies to
HIV and hepatitis C, as well as hepatitis B surface antigen.35
Rigorous testing and increased regulatory compliance add
expense to the manufacturing of Nanocoll and substantially
decreases the likelihood that modifications for performance
improvements will be commercialized. Tilmanocept is not
derived from blood and therefore can be synthesized at very
high scales without continual monitoring for new biological
‘‘threats’’ from the human blood supply.
There were two reasons for using the ‘‘3-sigma’’ rule.
First, the ‘‘3-sigma’’ rule is based on a statistical rationale
and is used extensively in the radiation sciences to define a
criteria known as the ‘‘Minimum Detectable Activity.’’36
When a measurement is greater than background by 3
times the standard deviation of the background, the prob-
ability that the measurement is truly different than
background is greater than 99.7 %. The measurement of
radioactivity is a counting process that follows a Poisson
distribution, which occurs when the process is the result of
many attempts and very few successes. The standard
deviation of a Poisson distribution is the square root of the
measurement. Consequently, the Minimum Detectable
Activity for a sentinel lymph node is 3 times the square
root of the background count rate, which can be obtained
by a single measurement. Second, the ‘‘10 %’’ was
empirically established for radiocolloids and may not be
applicable to a nonparticulate receptor-targeted radiophar-
maceutical.18 Due to its small size (7 nm) and high
receptor avidity, tilmanocept delivers significantly more
radioactivity to the sentinel lymph node and clears from the
injection site 5-fold faster than sulfur colloid. For example,
the UCSD breast cancer patients were studied with a pro-
tocol that used a single intradermal injection of 0.1 ml. A
total of 95 patients had at least 1 ‘‘hot’’ lymph node. The
count rate of the ‘‘hottest’’ lymph node from each patient
ranged from 375 cps to an excess of 999,999 cps, which is
the readout maximum of the Neo200 counting system.
Seven lymph nodes exceeded this count rate. The median
count rate of the ‘‘hottest’’ lymph node was 15,738 cps.
Appling the ‘‘10 % rule’’ when the ‘‘hottest’’ node has
15,000 cps would permit the surgeon to stop if the surgical
bed had a count rate of 1,500 cps or less. This would risk
leaving behind a lymph node that could be 1,500 cps and
by radiocolloid standards would be considered very ‘‘hot.’’
Such a lymph node would be almost 3 orders-of-magnitude
higher than background and would more than satisfy the
‘‘3-sigma rule,’’ which was our statistical basis for defining
a radioactive signal and, hence, a sentinel lymph node.
A sentinel lymph node definition based on the technical
criteria of ‘‘Minimal Detectable Activity’’ may not provide
the most efficient ‘‘stopping rule’’ for the mapping proce-
dure. Although a ‘‘stopping rule’’ for a receptor-targeted
agent such as [99mTc]tilmanocept will require a separate
study and may not be at all similar to the rule used for par-
ticulate radiotracers, a comparison of our results to the
‘‘10 % rule,’’ which is used for unfiltered and filtered
[99mTc]labeled sulfur colloid may be instructive.18,37–40 The
‘‘10 % rule’’ and the ‘‘3-sigma rule’’ identified the same
number of patients (n = 146) with at least 1 ‘‘hot’’ lymph
node. Consequently, the per-patient concordance rate was
the same using both rules. Additionally, defining the sentinel
node by the ‘‘10 % rule’’ did not alter the pathology status on
a per-patient basis. Also, 17 fewer sentinel lymph nodes were
defined as ‘‘hot’’ based on the ‘‘10 % rule.’’ Of these, 11
nodes were blue, and 2 of the 11 were pathology-positive.
In summary, these studies demonstrated that SLN
detection by [99mTc]tilmanocept is highly concordant to
SLN detection by VBD. [99mTc]Tilmanocept detected
more SLNs than VBD, and these additional SLNs
enhanced the detection of clinically important nodal
metastases. Given these results, this agent is safe and
provides a modern radiopharmaceutical for future advances
in sentinel lymph node mapping.
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